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Abstract 
Eosinophilia is common in childhood, and in
most cases it is mild and of limited clinical rel-
evance, being often secondary to allergy or
infections. In rare cases, eosinophilia may be
idiopathic or related to neoplastic aetiology.
When severe and protracted, it can cause
potentially irreversible organ or system dam-
age, whose prevention is the first priority in
the clinical management of hypereosinophilia.
We describe the case of a patient with very
severe eosinophilia, in whom antihistamines
proved to be effective and safe in contributing
to the eosinophil count normalization, thus
avoiding the use of steroids until the hypothe-
sis of an underlying neoplastic disorder was
reasonably excluded. 
Introduction
The finding of high eosinophil count is quite
frequent in childhood, and in most cases it is
mild and transient, but sometimes can be the
first sign of a severe pathological condition.
Hypereosinophilia is defined as a peripheral
blood absolute eosinophil count (AEC) higher
than 0.6?109/L (0.7?109/L in neonates).1,2
The degree of eosinophilia can be further
categorized into mild (AEC 0.6-1.5?109/L),
moderate (AEC 1.5-5?109/L), or severe (AEC
>5?109/L).3
Eosinophilia can be primary (idiopathic) or
secondary to allergy, infections, connective
tissue disease, or cancer. While mild
eosinophilia is frequent in childhood, being
most commonly related to allergy,1 moderate
and severe eosinophilia is rare. Usually, chil-
dren with allergic diathesis show mild to mod-
erate eosinophilia, with AEC rarely exceeding
1.0-2.0?109/L. Higher AEC may be the uncom-
mon yet possible first sign of neoplastic dis-
ease, sometimes being the result of a clonal
eosinophilic proliferation or secondary to
other neoplastic diseases (lymphoproliferative
or myeloproliferative diseases, and even solid
tumors).4 A diagnosis of hypereosinophilic
syndrome (HES) should be considered when
eosinophilia is sustained (>1.5?109/L) and
protracted with evidence of target organ dam-
age.3 HES is a myeloproliferative disorder with
multi-organ systemic involvement, that is fre-
quently associated with peculiar acquired
genetic aberrations (FIP1L1-PDGFRA fusion
gene).4 The therapy of HES is challenging and
encompasses the use of tyrosine-kinase
receptor inhibitors (e.g. imatinib) and some-
times allogenic hematopoietic stem cell trans-
plantation.5
Severe or protracted eosinophilia may
induce organ damage due to the toxic action of
pro-inflammatory cytokines released by the
eosinophils. The target organs and systems
most frequently involved are the heart, the
nervous system, and the skin. Involvement of
either the heart or the central nervous system
is responsible for significant morbidity and
mortality.6,7
Corticosteroids are useful in lowering the
AEC, but their use might mislead and delay the
diagnosis in patients in whom a malignant
hemopathy underlies eosinophilia. Ideally, the
use of steroids in patients with eosinophilia
should be started only when the diagnostic
process has led to a reasonable exclusion of an
underlying neoplastic disease.
Case Report
A 7-year-old boy was evaluated for malaise,
anorexia and recurrent fever. In the absence of
organomegaly, lymphadenopathy or other signs
of lymphoproliferative disease, a complete
blood count evidenced isolated very severe
hypereosinophilia, (white blood cells 70?109/L,
with 80% eosinophils), with normal haemoglo-
bin and platelets. The patient, as well as his
parents, reported a history of mild allergy. 
Peripheral blood smear showed a huge num-
ber of morphologically normal eosinophils,
without signs of lymphoproliferative disease or
myelodysplasia. 
Total immunoglobulin E (IgE) was elevated
(233 UI/mL n.v. <70) and the search for specif-
ic IgE - FAST - resulted positive for der-
matophagoides pteronyssinus, cat epithelium,
alternaria and parietaria, egg and milk; prick
tests for food and inhalants were negative.
Due to the very high eosinophil count, anti-
histamines were administered immediately
(cetirizine, 5 mg/day), in order to try and
reduce hypereosinophilia while avoiding the
use of corticosteroids. 
In order to exclude infections, the following
exams were performed: Toxocara and
Toxoplasma serology, Epstein-Barr virus serol-
ogy, throat swab, stool and urine culture,
Mantoux inthradermoreaction, stool parasito-
logical exam, the search for Aspergillum anti-
gen, Widal Wright serology, oculistic examina-
tion. All exams resulted negative. 
Autoimmunity (Coombs test, anti-nucleus
and anti DNA antibody, celiac disease screen-
ing and HLA DQ2 and DQ8 search) was nega-
tive. 
Chest X-ray and abdominal ultrasound were
normal. 
A bone marrow aspirate was performed, but
both morphology and flow cytometry disclosed
abundant eosinophils with no leukemic cells or
myelodysplasia. Chromosomal rearrangements
commonly associated with myeloid and lym-
phoblastic acute leukemia were negative.
Karyotype was 46,XY. The rearrangement
FIP1L1-PDGFRA, typical of HES, was negative
both on peripheral blood and on bone marrow.
The search for WT-1 (Wilms tumor gene) gene
copy number alteration, reported to be high in
HES,8 was negative. 
Within less then 2 weeks of treatment with
antihistamines, hypereosinophilia improved
significantly, and a normalizazion of AEC was
obtained in 12 days (0.46?109/L). 
After eosinophil count normalization, the
patient was discharged and followed-up with
periodical clinico-hematological controls.
Electrocardiogram and cadiac ultrasound were
repeated weekly and never showed cardiac
functional damage. Hepatic aminotransferases
and creatinine were always normal. No skin
rash was noticed. Neither intestinal bleeding
nor diarrhea was reported. 
Fifteen months later, in the absence of
newer signs or symptoms, eosinophils raised
again severely (AEC 45.4?109/L). Blood smear
and flow cytometry showed normal morphology
and immunophenotype. IgE was found to be
elevated again (156 UI/mL). 
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Case Report
Figure 2. Diagnostic work-up and treatment (specific and supportive) as proposed by the Authors. Antihistamines may be started safe-
ly and promptly to prevent organ damage, the best timing being after completing allergy exams. On the contrary, steroids should not
be administered until a diagnosis of hypereosinophilic syndrome or neoplastic disease is ruled out.
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The patient was immediately treated with
antihistamines again, and AEC lowered to nor-
mal values in 3 weeks (Figure 1). An allergen-
free diet was started; the patient has been fol-
lowed up for 12 months and at the time of writ-
ing his AEC was normal. 
Discussion and Conclusions
Allergy is among the most frequent cause
underlying eosinophilia, especially in children.
The typical clinical picture in allergic patients
with eosinophilia is mild-to-moderate AEC ele-
vation in presence of clinical manifestations of
allergic disease (rhinitis, conjunctivitis, skin
rash, eczema, urticaria, etc.) without relevant
signs of systemic organ or tissue involvement.
In our patient very severe eosinophilia
(highest AEC 70?109/L) was associated with
mild systemic symptoms with fever and
malaise, but no typical signs of allergic diathe-
sis. Clinical priorities for physicians were to
exclude a neoplastic etiology or HES, on one
hand, and to prevent potential system and
organ damage, on the other. 
The peculiarity of our patient was that the
extremely high AEC was secondary to allergy.
At presentation, we can hypothesize that AEC
was boosted by an unidentified viral infection,
that was probably the cause of fever, but this is
just speculative. 
A wide panel of clinical, haematological and
imaging exams reasonably excluded an under-
lying neoplastic disease. The translocation
FIP1L1-PGDFRA was negative on bone marrow
aspirate;4 furthermore, normal WT-1 quantita-
tive analysis,8 the presence of positivity to
allergogenic tests and the rapid and complete
normalization of AEC with antihistaminic
therapy led us to consider HES and neoplasia
as improbable aetiologies.
Very high levels of eosinophils are a possible
finding in patient with allergy, especially when
associated with other pro-inflammatory events
such as viral or bacterial infections, and very
severe eosinophilia is not invariably associat-
ed with myeloproliferative hypereosinophilic
syndrome or other neoplastic disease. 
Eosinophil morphology, normality of cell
blood count and other hematopoietic series,
response to antihistaminic treatment and pos-
itivity of allergogenic assays can ease the diag-
nosis of allergic eosinophilia. Hematologic and
imaging exams can help exclude the presence
of neoplastic lesions that could indirectly lead
the eosinophilic proliferation. 
The surveillance, prevention and early treat-
ment of systemic and organ damage due to
sustained and prolonged eosinophilia remains
one of the mainstays in the care of
eosinophilic patients and must accompany all
steps of the diagnostic and therapeutic
process. The effectiveness of antihistamines
in severe hypereosinophilia is not described in
literature, but our case supports the hypothe-
sis that antihistaminic therapy may some-
times be sufficient to reduce AEC, and that
potentially it can be used as a first-line thera-
py in a subset of patients with severe
eosinophilia. The use of second-generation
antihistamines at conventional dosage is rec-
ommended, due to the low incidence of collat-
eral effect, even when used for long periods.
The use of steroidal drugs should be avoided in
the diagnostic phase, and limited to those
patients in whom a complete diagnostic
process has led to a reasonable exclusion of an
underlying neoplastic disease (Figure 2).
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Figure 1. Absolute eosinophil count trend and concomitant therapy during the first (A) and the second hospitalization (B).
